Comorbidities associated with psoriasis: An experience from the Middle East

Journal of Dermatology

Volumn 37, Issue 2, 2010, Pages 146-155

  Al Mutairi, Nawaf ^a   Al Farag, Shahat ^a   Al Mutairi, Ahmed ^b   Al Shiltawy, Mazen ^a  

^a FARWANIYA HOSPITAL   (Kuwait)

^b Ahmadi Hospital   (Kuwait)

Author keywords

Associations; Comorbidities; Metabolic syndrome; Psoriasis vulgaris

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTHRITIS; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE EAST; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; PSORIASIS VULGARIS; RISK FACTOR; SEX DIFFERENCE; SMOKING;

ADULT; AGED; ARTHRITIS; BODY MASS INDEX; CASE-CONTROL STUDIES; COMORBIDITY; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MIDDLE EAST; NEOPLASMS; OBESITY; PREVALENCE; PSORIASIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING; YOUNG ADULT;

EID: 76249101957     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2009.00777.x     Document Type: Article

References (56)

1. Christophers E. Psoriasis epidemiology and clinical spectrum. Clin Exp Dermatol 2001 26 : 314 320.
2. Neimann AL, Porter SB, Gelfand JM. Epidemiology of psoriasis. Expert Rev Dermatol 2006 1 : 63 75.
3. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005 64 (Suppl 2 ii30 ii36.
4. Christophers E. Comorbidities in psoriasis. J Eur Acad Dermatol Venereol 2006 20 (Suppl 2 52 55.
5. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of Myocardial Infarction in Patients with Psoriasis. J Am Med Assoc 2006 (Oct 11 292 (14 1735 1741. (Pubitemid 44547793)
6. Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007 (Dec 143 (12 1493 1499.
7. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983 67 (3 361 370.
8. National Institute of Health. Third report of the National Cholesterol Education Program Export Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary. NIH pub no. 01-3670. Bethesda, MD : National Institute of Health, National Heart, Lung and Blood Institute, 2001.
9. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995 32 : 982 986.
10. Pearce DJ, Morrison AE, Higgins KB et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005 16 : 319 323.
11. Gulliver WP. Importance of Screening for Comorbidities in Psoriasis Patients. Expert Rev Dermatol 2008 3 (2 133 135.
12. Gulliver WP Genetic targets for the future treatment of psoriasis including HLA-Cw6. Presented at: 21st World Congress of Dermatology, 30 September-5 October 2007, Buenos Aires, Argentina.
13. Rahman P, O'Reilly DD. Psoriatic arthritis: genetic susceptibility and pharmacogenetics. Pharmacogenomics 2008 9 (2 195 205.
14. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006 314 : 1461 1463.
15. Cargill M, Schrodi SJ, Chang M et al. A large-scale genetic association study confirms IL-12B and leads to the identification of IL-23R as psoriasis-risk genes. Am J Hum Genet 2007 80 : 273 290.
16. Sherer Y, Shoenfeld Y. Mechanisms of disease: atherosclerosis in autoimmune diseases. Nat Clin Pract Rheumatol 2006 2 : 99 106.
17. Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004 19 (3 225 230.
18. Ena P, Madeddu P, Glorioso N, Cerimele D, Rappelli A. High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients. Acta Cardiol 1985 40 : 199 205.
19. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003 24 (1 278 301.
20. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 352 : 1685 1695.
21. Bonifati C, Carducci M, Cordiali Fei P et al. Correlated increases of tumour necrosis factor-α, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients - relationships with disease severity. Clin Exp Dermatol 1994 19 : 383 387.
22. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005 112 : 3066 3072.
23. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between Psoriasis and the Metabolic Syndrome, A Cross-Sectional Study. Dermatology 2007 216 : 152 155.
24. Gisondi P, Tessari G, Conti A et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007 157 : 68 73.
25. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. J Am Med Assoc 2002 288 : 2709 2716.
26. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 2003 278 (46 45777 45784.
27. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006 6 : 772 783.
28. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an update. Clin Endocrinol 2006 64 : 355 365.
29. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003 108 : 2957 2963.
30. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 1994 94 : 1543 1549.
31. Prodanowich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005 52 (2 262 267.
32. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2005 64 (5 765 766.
33. Simonetti O, Ferretti G, Salvi A, Offidani AM, Bossi G. Plasma lipid changes in psoriatic children. Dermatology 1992 185 : 96 100.
34. Vahlquist C, Michaelsson G, Vessby B. Serum lipoproteins in middle-aged men with psoriasis. Acta Derm Venereol 1987 67 : 12 15.
35. Mallbris L, McInnes IB. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006 54 : 614 621.
36. Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005 125 : 61 67.
37. Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007 157 : 649 655.
38. Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am J Physiol Endocrinol Metab 2006 290 (5 E961 E967.
39. Ryder MI, Saghizadeh M, Ding Y, Nguyen N, Soskolne A. Effects of tobacco smoke on the secretion of interleukin-1 β, tumor necrosis factor-a, and transforming growth factor-β from peripheral blood mononuclear cells. Oral Microbiol Immunol 2002 17 : 331 336.
40. Lee FI, Bellary SV, Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 1990 85 : 962 963.
41. Gladmann DD, Antoni C, Mease P, Clegg DO, Nash P et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005 64 (Suppl II14 II17.
42. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK et al. Psoriatic arthritis (PSA) - an analysis of 220 patients. Q J Med 1987 62 : 127 141.
43. Dreiher J, Weitzman D, Shapiro J, Davidovici B, Cohen AD. Psoriasis and chronic obstructive pulmonary disease: a case-control study. Br J Dermatol 2008 159 (4 956 960.
44. Agusti A, MacNee W, Donaldson K, Cosio M. Hypothesis: does COPD have an autoimmune component? Thorax 2003 58 : 832 834.
45. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006 126 (10 2194 2201.
46. Laharie D, Terrebonne E, Vergniol J, Chanteloup E, Chabrun E, Couzigou P. [The liver and methotrexate]. Gastroenterol Clin Biol 2008 (Feb 32 (2 134 142.
47. Eisen AZ, Seegmiller JE. Uric acid metabolism in psoriasis. J Clin Invest 1961 40 : 1486 1494.
48. Goldman M. Uric acid in the etiology of psoriasis. Am J Dermatopathol 1981 3 (4 397 404.
49. Gschnait F, Ita E. Serum uric levels in patients with psoriasis vulgaris. Wien Klin Wochenschr 1978 90 : 309 311.
50. Schmitt JM, Ford DE. Role of depression in quality of life for patients with psoriasis. Dermatology 2007 215 (1 17 27.
51. Levenson JL. Psychiatric Issues in Dermatology, Part 1: atopic Dermatitis and Psoriasis. Prim Psychiatry 2008 15 (7 35 38.
52. Gupta MA, Gupta AK, Schork NJ, Ellis CN. Depression modulates pruritus perception: a study of pruritus in psoriasis, atopic dermatitis, and chronic idiopathic urticaria. Psychosom Med 1994 56 (1 36 40.
53. Gerdes S, Zahl VA, Knopf H, Weichenthal M, Mrowietz U. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008 159 : 1116 1123.
54. Wakkee M, Thio HB, Prens EP, Sijbrands EJ, Neumann HA et al. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Atherosclerosis 2007 190 : 1 9.
55. Vasku V, Kankova K, Vasku A et al. Gene polymorphisms (G82S, 1704G/T, 2184A/G and 2245G/A) of the receptor of advanced glycation end products (RAGE) in plaque psoriasis. Arch Dermatol Res 2002 294 : 127 1230.
56. Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: tumor necrosis factor α (TNF-α) blockade in psoriasis and psoriatic arthritis. Clin Dermatol 2003 21 : 392 397.